NCT02756130View on ClinicalTrials.gov

Birinapant and Carboplatin in Treating Patients and Targeting Recurrent High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (HGSOC)

PHASE1/PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

August 1, 2018

Primary Completion Date

February 1, 2020

Study Completion Date

February 1, 2021

Conditions
High Grade Fallopian Tube Serous AdenocarcinomaHigh Grade Ovarian Serous AdenocarcinomaPrimary Peritoneal High Grade Serous AdenocarcinomaRecurrent Fallopian Tube CarcinomaRecurrent Ovarian CarcinomaRecurrent Primary Peritoneal Carcinoma
Interventions
DRUG

Birinapant

Given IV

DRUG

Carboplatin

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Pharmacological Study

Correlative studies

Trial Locations (1)

90095

UCLA / Jonsson Comprehensive Cancer Center, Los Angeles

Sponsors
All Listed Sponsors
collaborator

California Institute for Regenerative Medicine (CIRM)

OTHER

collaborator

TetraLogic Pharmaceuticals

INDUSTRY

collaborator

Alpha Stem Cell Clinic (ASCC)

UNKNOWN

lead

Jonsson Comprehensive Cancer Center

OTHER

NCT02756130 - Birinapant and Carboplatin in Treating Patients and Targeting Recurrent High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (HGSOC) | Biotech Hunter | Biotech Hunter